Recently, a study reported reduced migration and invasion of different prostate cancer cell lines in response to two other CDK8/CDK9 inhibitors, CCT251545 and G02788177.93–1 [[76], [77],196]. This evidence concerns the gene CDK9 and prostate cancer.